Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Utikal, J; Ugurel, S; Kurzen, H; Erben, P; Reiter, A; Hochhaus, A; Nebe, T; Hildenbrand, R; Haberkorn, U; Goerdt, S; Schadendorf, D.
Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses.
Arch Dermatol. 2007; 143(6):736-740
Doi: 10.1001/archderm.143.6.736
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Ugurel-Becker Selma
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: Systemic non-Langerhans cell histiocytoses are disorders characterized by the accumulation of histiocytes that do not meet the criteria for Langerhans cells in various organs. So far, no causative treatment is known. Observations: Herein, we report the case of a 41-year-old man with Rosai-Dorfman disease, a form of systemic non-Langerhans cell histiocytoses, with histiocytic infiltrations in the skin, bone marrow, liver, and spleen. Histiocytes were positive for the imatinib target proteins platelet-derived growth factor receptor 0 and KIT. The disease completely responded to treatment with 400 to 600 mg daily of imatimb for more than 7 months. Conclusion: This case shows that imatimb is a powerful treatment option for patients with non-Langerhans cell histiocytoses.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antineoplastic Agents - administration and dosage Antineoplastic Agents - therapeutic use
- Diagnosis, Differential -
- Histiocytosis, Non-Langerhans-Cell - diagnosis Histiocytosis, Non-Langerhans-Cell - drug therapy Histiocytosis, Non-Langerhans-Cell - pathology Histiocytosis, Non-Langerhans-Cell - radionuclide imaging
- Humans -
- Magnetic Resonance Imaging -
- Male -
- Piperazines - administration and dosage Piperazines - therapeutic use
- Positron-Emission Tomography -
- Protein Kinase Inhibitors - administration and dosage Protein Kinase Inhibitors - therapeutic use
- Protein-Tyrosine Kinases - antagonists and inhibitors
- Pyrimidines - administration and dosage Pyrimidines - therapeutic use
- Severity of Illness Index -